Device Trial Radar · NCT07928908
Transcranial Magnetic Therapy (TMS) for Treatment of Perinatal Depression
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Sep 23, 2026
Primary completion
Sep 2028
Study completion May 2029
Sponsor
- Lead sponsor
- Rana JawishAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 10, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- Female only, from 22 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the use of transcranial magnetic stimulation (TMS) to treat depression during pregnancy and the first year after childbirth. TMS is a noninvasive treatment that uses magnetic pulses applied to the scalp to stimulate areas of the brain involved in depression. The main goal of the study is to determine whether TMS treatment is feasible, acceptable, and safe for women with perinatal depression. The study will also collect preliminary information about whether TMS reduces symptoms of depression and whether improvements are maintained after treatment. Up to 100 women age 22 years and older who have major depression and are either 12 to 28 weeks pregnant or within 12 months after giving birth will participate. All participants will receive TMS; there is no placebo or comparison group. Participants will receive 20 to 36 TMS treatment sessions over approximately 4 to 8 weeks, with up to five sessions per week. Depression and other mental health symptoms, treatment attendance, satisfaction with treatment, and safety will be assessed before, during, and approximately one month after TMS treatment. The study hypothesis is that TMS will be a feasible and acceptable treatment for women with perinatal depression, as shown by participants completing and adhering to treatment, acceptable treatment satisfaction, and appropriate safety outcomes. The study will also explore whether depressive symptoms improve during TMS treatment and whether improvement is sustained one month after treatment. For women who participate while pregnant, the study team will review maternal and infant medical records approximately six months after delivery to assess pregnancy, delivery, postpartum, and infant health outcomes.
Conditions
- Perinatal Depression
Interventions
Transcranial Magnetic Stimulation (TMS)Device
Participants will receive active transcranial magnetic stimulation (TMS) using the NeuroStar TMS system, targeting the left dorsolateral prefrontal cortex (DLPFC). Treatment will use FDA-cleared stimulation parameters for major depressive disorder, including standard repetitive TMS (rTMS) at 10 Hz (3,000 pulses per session) or intermittent theta burst stimulation (iTBS; 600 pulses per session). Stimulation intensity will be set at 80-120% of each participant's resting motor threshold. Participants will receive one session per day, up to five days per week, for a total of 20-36 sessions over 4-8 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Retention RateTime frame: 8 weeks post baseline
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Huntsman Mental Health Institute
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.